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Abstract 85 
 86 
Purpose:  To compare the efficacy of Behavior Activation+ Low Vision Rehabilitation with 87 
Supportive Therapy+ Low Vision Rehabilitation to prevent depressive disorders in 88 
patients with Age-Related Macular Degeneration (AMD).  89 
 90 
Design:  Single-masked, attention controlled randomized clinical trial with outcome 91 
assessment at 4 months.   92 
 93 
Participants:  Patients with AMD and subsyndromal depressive symptoms attending 94 
retina practices (N = 188). 95 
 96 
Interventions:  Prior to randomization, all subjects had two outpatient low vision 97 
rehabilitation visits (LVR), and were then randomized to in-home Behavior Activation 98 
(BA+LVR) or Supportive Therapy (ST+LVR).  Behavior Activation is a structured 99 
behavioral treatment that aims to increase adaptive behaviors and achieve valued 100 
goals.  Supportive Therapy is a nondirective, psychological treatment that provides 101 
emotional support and controls for attention 102 
 103 
Main Outcome Measures:  Diagnostic and Statistical Manual IV-defined depressive 104 
disorder based on the Patient Health Questionnaire-9 (primary outcome); Activities 105 
Inventory (AI); National Eye Institute Vision Function Questionnaire - 25 plus 106 
Supplement (NEI VFQ); and NEI VFQ Quality of Life (secondary outcomes). 107 
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Results:  At 4 months, 11 (12.6%) BA+LVR subjects and 18 (23.4%) ST+LVR subjects 108 
developed a depressive disorder (Relative Risk (RR) 0.54; 95% Confidence Interval (CI) 109 
[0.27, 1.06]; p = 0.067).  In planned adjusted analyses the RR was 0.51; (95% CI 0.27, 110 
0.98; p = 0.04).  A mediational analysis suggested that BA+LVR prevented depression 111 
to the extent that it enabled subjects to remain socially engaged.  BA+LVR was also 112 
associated with greater improvements in functional vision than ST+LVR but there was 113 
no statistically significant between-group difference.  There was no statistically 114 
significant change or between-group difference in quality of life. 115 
 116 
Conclusions:  An integrated mental health and low vision intervention halved the 117 
incidence of depressive disorders  relative to standard outpatient low vision 118 
rehabilitation in patients with AMD.  As the population ages, the number of persons with 119 
AMD and the adverse effects of comorbid depression will increase.  Promoting 120 
interactions between ophthalmology, optometry, rehabilitation,  psychiatry, and 121 
behavioral psychology may prevent depression in this population.   122 
 123 
 124 
 125 
 126 
 127 
 128 
 129 
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Age-related macular degeneration (AMD) is the leading cause of severe vision loss in 130 
older adults, with 6.5% having early signs of disease and 0.8% having late disease (i.e., 131 
neovascular AMD or geographic atrophy).1  By 2050, 17.8 million persons will have early 132 
AMD and 3.8 million will have late AMD.2  This will confront ophthalmologists, healthcare 133 
decision makers, insurers, and family members with the need to care for many visually 134 
disabled older persons.  Although antiangiogenic treatments have greatly improved the 135 
prognosis of neovascular AMD, the majority of treated patients do not regain lost 136 
vision.3, 4  No medical treatment is available for patients with geographic atrophy.    137 
Thus, many patients with AMD experience irreversible vision loss, impaired functional 138 
vision, and diminished quality of life.5, 6 About 10%-30% of patients with AMD develop 139 
clinically significant depression, which is associated with higher levels of disability, 140 
medical costs, and mortality.7-9 Despite the substantial adverse effects of depression, 141 
many depressed persons receive no treatment because they perceive depression as a 142 
personal failure or an expected part of aging, they are uncertain how to access specialty 143 
mental health car, or their physicians lack the expertise or time to effectively diagnose 144 
and treat depression.10 145 
 146 
To investigate an integrated model of treatment, we conducted the Low VIsion 147 
Depression Prevention TriAL (VITAL).  VITAL is a randomized controlled trial that 148 
compared the efficacy of Behavior Activation+ Low Vision Rehabilitation (BA+LVR) with 149 
Supportive Therapy+ Low Vision Rehabilitation (ST+LVR) to prevent progression to 150 
more severe depressive disorders in patients with bilateral AMD and early signs of 151 
depression.  Prior to randomization, all subjects had two visits with low vision 152 
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optometrists.  Subjects were then randomized to in-home Behavior Activation or 153 
Supportive Therapy.  In the former, occupational therapists delivered Behavior 154 
Activation to address depression and functional deficits due to vision loss.  Behavior 155 
Activation is a structured behavioral treatment that aims to increase adaptive behaviors 156 
and achieve valued goals.11 In ST+LVR, master’s level therapists delivered in-home 157 
Supportive Therapy, which is a nondirective, psychological treatment that provides 158 
emotional support and controls for attention.12 The primary hypothesis of VITAL was 159 
that BA+LVR would be more effective than ST+LVR to prevent depressive disorders 160 
and improve functional vision and quality of life. 161 
 162 
 163 
 164 
 165 
 166 
 167 
 168 
 169 
 170 
 171 
 172 
 173 
 174 
 175 
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Methods: 176 
 177 
Eligibility and Trial Design:  Institutional Review Board (IRB)/Ethics Committee 178 
approval was obtained to conduct the Low Vision Depression Prevention Trial (clinical 179 
trials.gov NCT00769015).  All subjects provided informed consent; study procedures 180 
were HIPAA-compliant and adhered to the tenets of the Declaration of Helsinki.  181 
Subjects were recruited from a large private retina practice associated with the Wills 182 
Eye Hospital, Philadelphia, PA, who met the following inclusion criteria:   183 
1) age over 65 years; 2) bilateral AMD (either neovascular disease or geographic 184 
atrophy); 3) best corrected visual acuity worse than 20/70 in the better-seeing eye;  185 
4) more than 5 antiangiogenic injections if the better eye had neovascular disease, or 186 
no injections in the previous 3 months; 5) moderate difficulty performing a valued vision-187 
dependent activity; and 6) subthreshold depressive symptoms, defined as a Patient 188 
Health Questionnaire-9 score greater than 5, or depressed mood or anhedonia several 189 
days per week.13 The exclusion criteria were: 1) on-going or anticipated antiangiogenic 190 
treatment; 2) current Diagnostic and Statistical Manual (DSM) IV-defined depressive 191 
disorder;14 3) uncontrolled glaucoma, diabetic retinopathy, corneal dystrophy, or 192 
anticipated cataract surgery; and 4) cognitive impairment on an abbreviated version of 193 
the Mini-Mental Status Examination that omits vision-dependent items.15    194 
 195 
The study statistician randomized eligible subjects using a random-numbers table, 196 
sealed envelopes containing treatment assignments, and a fixed randomization scheme 197 
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with a 1:1 allocation ratio to the 2 study groups, stratified by severity of vision loss 198 
(visual acuity of 20/70 to 20/100 vs. worse than 20/100 in the better eye).  199 
 200 
Treatment Interventions: 201 
 202 
Low Vision Optometry:  One of five community-based low vision optometrists 203 
evaluated and treated all subjects prior to randomization.  The two clinic visits included 204 
assessment of vision function (e.g., visual acuity, refraction), and prescribing devices 205 
and providing instruction on their use.  The study provided $350 to all subjects to 206 
purchase a basic set of optical devices.  Following these visits, subjects were 207 
randomized to Behavior Activation, which was delivered by one of five occupational 208 
therapists, or Supportive Therapy, which was delivered by one of three master’s level 209 
therapists (e.g., social workers).   210 
 211 
Behavior Activation (BA) + Low Vision Rehabilitation (LVR) [BA+LVR]:  The 212 
occupational therapists delivered 6 in-home, one hour Behavior Activation sessions 213 
over 8 weeks.  Treatment emphasized the link between action, mood, and mastery, and 214 
promoted self-efficacy and social connection as ways to improve mood and function and 215 
counter self-defeating behaviors (e.g., social withdrawal).11 The occupational therapist 216 
suggested environmental modifications to improve function and, with the subject, 217 
developed Action Plans to accomplish valued personal and functional goals. The Action 218 
Plans drew on rehabilitation principles (e.g., breaking down tasks into manageable 219 
steps), were integrated into daily routines, and focused on increasing social activities 220 
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and reducing vision-related task difficulty.  The latter was accomplished by increasing 221 
magnification, improving lighting, highlighting objects with high-contrast tape, and 222 
simplifying routines.   223 
 224 
Supportive Therapy (ST) + Low Vision Rehabilitation (LVR) [ST+LVR]:  Supportive 225 
Therapy therapists delivered 6 in-home, one hour sessions over 8 weeks to facilitate 226 
discussion of illness, disability, and vision loss.  Treatment facilitated personal 227 
expression about vision loss and disability and, in this trial, controlled for the nonspecific 228 
effects of attention.12  229 
 230 
Treatment Fidelity:  All sessions were audiotaped and an experienced psychotherapy 231 
researcher (MTH) and a certified low vision OT reviewed one-third of randomly selected 232 
tapes.  On a scale from 1 to 5, with 5 representing better standing, the global treatment 233 
fidelity ratings of the occupational therapists and supportive therapists were above 234 
satisfactory (i.e., ≥ 3) at 3.5 (1.2) and 4.9 (.80), respectively.  235 
 236 
Study Measures:  Research assistants evaluated subjects in their homes masked to 237 
treatment assignment at baseline and 4 months to assess the following variables: 238 
 239 
1. Depression:  The primary outcome was a DSM IV diagnosis of major or minor 240 
depression based on the Patient Health Questionnaire-9 (PHQ-9).13 The PHQ-9 241 
includes the 9 criteria that define DSM IV diagnoses of depression and is valid in low 242 
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vision patients.16 A scoring algorithm determines if the profile of symptoms meets 243 
categorical diagnoses of depression. 244 
 245 
2. Self-Reported Functional Vision:  This was assessed using the Activities Inventory 246 
and the National Eye Institute Vision Function Questionaire-25 (NEI VFQ) near and 247 
distance activities subscales.17, 18 The Activities Inventory measures the ability to 248 
achieve general vision-dependent activity goals, and perform specific vision-dependent 249 
cognitive and motor tasks.  An overall functional vision variable is estimated by Rasch 250 
analysis.19 The NEI VFQ rates difficulty performing daily activities.  Standardized scores 251 
range from 0 to 100, with higher scores indicating better function. 252 
 253 
3. Vision-Related Quality of Life:  This was a latent variable comprised of the NEI 254 
VFQ social functioning, mental health, role difficulties, and dependency subscales.   255 
Standardized scores range from 0 to 100 with higher scores indicating better life quality. 256 
 257 
4. Vision Status:  This included standardized measurement of distance and near visual 258 
acuity, contrast sensitivity, and the size and location of central scotomas.   259 
 260 
5. Physical Health Status:   This was assessed with the Chronic Disease Score and 261 
the Medical Outcomes Study-6 (MOS-6).  The Chronic Disease Score yields a weighted 262 
score based on medication use that reflects severity of medical comorbidity.20  The 263 
MOS-6 yields a global index of self-rated physical and mental health.21  Higher scores 264 
on both scales reflect worse health status. 265 
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 266 
6. Personality:  The Revised Neuroticism, Extroversion, Openness Five Factor 267 
Inventory (NEO-FFI) was used to assess the personality traits of neuroticism, 268 
conscientiousness, and openness to experience.22  Higher scores reflect higher 269 
standing on a given trait. 270 
 271 
7. Behavioral Activation for Depression Scale:  This scale measures engagement in 272 
social and occupational activities.23 Its four subscales tap:  activation; avoidance/ 273 
rumination; work/school impairment; and social impairment.  Scores range from 0 to 42; 274 
higher scores reflect worse functioning.   275 
 276 
8. Device Use:  Subjects rated their frequency of use of various low vision aids (e.g., 277 
task lighting) and devices (e.g., magnifiers) to improve visual ability. 278 
 279 
Statistical Methods 280 
 281 
A sample of 144 subjects provided 90% power to detect a 50% reduction in depression 282 
incidence at 4 months.  This calculation assumed equal numbers in the 2 visual acuity 283 
strata (with a 60% incidence rate of depression in controls in the worse vision stratum, 284 
and 50% in the better vision stratum) using a 2-sided continuity-corrected Mantel-285 
Haenszel test of the hypothesis that the risk ratio equaled 1.  Type I error rate was set 286 
at 5%.  We planned to recruit an additional 56 subjects to control for possible 287 
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improvements in visual acuity in subjects who might receive additional antiangiogenic 288 
treatments during the study and to account for a 10% attrition rate.      289 
 290 
Continuous baseline demographic and clinical characteristics were summarized using 291 
means and standard deviations, and categorical variables using counts and 292 
percentages.  For the primary efficacy analysis, we calculated stratum-specific relative 293 
risks and 95% confidence intervals for the incident depressive disorder at 4 months 294 
using Mantel-Haenszel methods.  Poisson regression with robust standard errors was 295 
used to compute estimates of the intervention’s effect on depression incidence adjusted 296 
for important baseline variables.24  The stratification variable (visual acuity) and baseline 297 
depression score (PHQ-9) were included as adjustment covariates in all models.   Other 298 
baseline covariates considered were related to the outcome at the bivariate level with p 299 
values < .10.  Linear mixed effects models were used to analyze all available Activities 300 
Inventory, NEI VFQ, and Behavioral Activation for Depression Scale data at baseline 301 
and 4 months.  We extended the mixed effects model to jointly analyze the four NEI-302 
VFQ quality of life subscales at baseline and 4 months to account for correlation among 303 
the four subscales and allow for a multivariate test of group differences in change over 304 
time.25, 26    Mediation analysis was performed using structural equation models.27   305 
 306 
 307 
 308 
 309 
 310 
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Results   311 
 312 
Figure 1 depicts the study flow chart.  From July 2009 to February 2013 we reviewed 313 
the records of 2,324 potentially eligible patients.  Of them, 1,158 (49.8%) declined 314 
participation, 706 (30.4%) were ineligible, and 272 (11.8%) could not be reached.  315 
There were no significant differences between enrolled subjects and eligible patients 316 
who declined participation in age, sex, or visual acuity (data not shown).  Baseline 317 
assessments were conducted on 222 subjects.  Of them, 23 subjects declined further 318 
participation and 11 were ineligible.  Thus, 188 subjects were randomized to the two 319 
study interventions.  Their average age was 84.0 years (standard deviation 6.94); 320 
70.2% were women and 50.0% lived alone.  As shown in Table 1, the demographic and 321 
clinical characteristics of subjects in the two treatment groups were similar except that 322 
BA+LVR subjects were somewhat older and married.   323 
 324 
From baseline to 4 months, 19 (10.1%) subjects dropped from the trial (7 Behavior 325 
Activation; 12 Supportive Therapy).  These subjects had higher baseline Chronic 326 
Disease Scores (i.e., worse medical status) and worse visual acuity than retained 327 
subjects but did not differ in PHQ-9 or MOS-6 scores (data not shown).  After 4 months, 328 
there were no significant within-group or between-group changes in visual acuity, 329 
contrast sensitivity, scotoma size, Chronic Disease Score, or Behavioral Activation for 330 
Depression Scale scores (data not shown). The mean number of treatment sessions 331 
that BA+LVR and ST+LVR subjects received were 5.7 (1.1) and 5.0 (1.9), respectively.   332 
 333 
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Table 2 shows that 11 (12.6%) BA+LVR subjects and 18 (23.4%) ST+LVR subjects 334 
developed a depressive disorder by 4 months (Relative Risk (RR) 0.54; 95% 335 
Confidence Interval (CI) [0.27, 1.06]; p = 0.067).  The treatment effect was more evident 336 
in subjects in the worse vision stratum (RR 0.37; 95% CI [0.14, 0.96]) than in subjects in 337 
the better vision stratum (RR 0.80; 95% CI [0.29, 2.18]).  Overall, the absolute risk 338 
reduction was 11% and the number needed to treat (NNT), or number of patients who 339 
need to be treated to prevent one additional case of depression, was 9.  For subjects 340 
with worse vision, the risk reduction was 20% and the NNT was 5.  For subjects with 341 
better vision, the risk reduction was 3.4% and the NNT was 29.  Baseline covariates that 342 
were associated with incident depression were higher MOS-6 score (i.e., worse self-343 
rated health) and NEO-PPI neuroticism score (i.e., the trait tendency to experience 344 
negative affects).   345 
 346 
Table 3 shows the results of an adjusted regression analysis that included treatment 347 
group, vision stratum, and baseline better eye scotoma size and PHQ-9, MOS-6, and 348 
neuroticism scores.  The regression revealed that BA+LVR subjects were significantly 349 
less likely to develop a depressive disorder than ST+LVR subjects after adjustment for 350 
the covariates (RR 0.51; 95% CI [0.27, 0.98]; p = 0.04).  Higher MOS-6 score remained 351 
an independent predictor of incident depression (RR 1.13 [95% CI [1.04, 1.21]) for each 352 
1 point increase; p = 0.014).   353 
 354 
To examine the potential impact of attrition, we conducted three separate sensitivity 355 
analyses.  In the first analysis, all subjects with missing data who were alive at 4 months 356 
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were considered as depressed.  The stratum-adjusted RR was 0.56 (95% CI 0.34, 357 
0.92); p=0.018.  In the second analysis, all were considered not depressed.  The 358 
stratum-adjusted RR was 0.58 (0.29, 1.16); p=0.12.  In the third analysis, we used 359 
multiple imputation to create 100 data sets with imputed depression status for patients 360 
alive but without follow-up data.  The imputation model included vision stratum, PHQ-9 361 
score, and the other baseline covariates that were significantly related to depression 362 
incidence.  The relative risk of incident depression was 0.56 (95% CI 0.29, 1.10); 363 
p=0.083.  These analyses suggest that attrition did not impact the observed treatment 364 
effect to a substantial degree. 365 
 366 
Table 4 shows change in Activities Inventory, NEI-VFQ functional vision and quality of 367 
life, and Behavioral Activation for Depression Scale subscale scores at 4 months by 368 
treatment group.  Activities Inventory scores improved in both treatment groups.  369 
Although the effect was larger in BA+LVR (effect size = 0.72) than ST+LVR (effect size 370 
= 0.56), there was no statistically significant difference between groups.  On the NEI 371 
VFQ, BA+LVR subjects had a statistically significant improvement in near activities 372 
(p=0.007) whereas ST+LVR subjects did not (p=0.20).  In spite of this within-group 373 
difference, there was no statistically significant between-group difference (p=0.34). 374 
There were no significant within-group changes or between-group differences in distant 375 
activities or quality of life.  BA+LVR subjects used a greater number of low vision 376 
devices than ST+LVR subjects [3.7 (1.5) vs. 2.9 (1.6); p = .003].  377 
 378 
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ST+LVR patients had significant declines in the Behavioral Activation for Depression 379 
Scale Social Impairment [mean change = -1.14 (-2.08, 0.21); p=0.02] while BA+LVR 380 
subjects had no decline.  Figure 2 shows a significant effect of treatment on change in 381 
the Social Impairment (a), a significant association between change in Social 382 
Impairment and incidence of depression (b), and a nearly significant indirect effect of 383 
treatment on depression (a x b).  These data suggest that change in Social Impairment 384 
at least partially mediated the relationship between treatment group and incident 385 
depression, such that BA+LVR prevented depression to the extent that it enabled 386 
treated subjects to remain socially engaged. 387 
 388 
 389 
 390 
 391 
 392 
 393 
 394 
 395 
 396 
 397 
 398 
 399 
 400 
 401 
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Discussion 402 
  403 
We found that an integrated mental health and low vision intervention halved  the 404 
incidence of depressive disorders (i.e., 12.6% versus 23.4%) relative to standard 405 
outpatient low vision rehabilitation in a high risk population of patients with AMD.  406 
Previous studies indicate that the incidence of depression in the absence of any 407 
rehabilitative treatment in patients with AMD ranges from 20%-28%.28, 29 The preventive 408 
efficacy of BA+LVR was strong, with a NNT of 9 to prevent 1 case of depression.  For 409 
subjects with worse vision, the NNT was 5, a remarkably good result.  By comparison, 410 
the NNT is 38 for intensive glycemic control over 4 years to prevent one case of 411 
clinically important diabetic retinopathy.30  A mediation model suggested that social 412 
activation accounted for BA+LVR’s therapeutic effect.   413 
 414 
BA+LVR was also associated with improved near functional vision.  Although ST+LVR 415 
was associated with some but lesser improvement, the observed differences were not 416 
statistically significant.  The low vision optometry treatment that all subjects received 417 
likely accounts for improvements in both groups.  We found no significant changes in 418 
distance functional vision because BA+LVR focused on near activities.  The quality-of-419 
life measures failed to show a statistically or clinically significant change, likely reflecting 420 
the insensitivity of the measures to change.31, 32   We also found that worse self-rated 421 
health was  associated with incident depression independent of treatment.  This finding 422 
indicates that patients with worse health perceptions require more intensive 423 
interventions.33 424 
18 
 
 
 425 
VITAL is the first clinical trial to test a collaborative mental health care model that was 426 
integrated into an ophthalmologic setting.  The strengths of this trial include systematic 427 
recruitment, successful randomization, low attrition, high subject adherence to protocol-428 
driven treatments, maintenance of treatment fidelity, and control for attention.  429 
Generalizability and durability of treatment effects are uncertain, however, given the 430 
unique characteristics of the sample, the high refusal rate, and the relatively short 431 
follow-up period.  A second limitation is reliance on the PHQ-9 for depression diagnosis 432 
rather than on a clinical interview.  Despite these limitations, VITAL contributes to the 433 
growing literature on the benefits of LVR.  The Low Vision Intervention Trial (LOVIT) 434 
demonstrated the efficacy of outpatient LVR to improve reading, mobility, information 435 
processing, and visual motor skills.34  Horowitz et al found that optical device use 436 
reduced functional disability and depressive symptoms in low vision patients.35  Brody et 437 
al found that a psychological self-management intervention improved well-being in 438 
patients with AMD, and we previously demonstrated the benefits of  Problem Solving 439 
Therapy in patients with AMD.28, 36, 37 These studies indicate that LVR programs, 440 
especially those that emphasize social engagement,  benefit patients with chronic vision 441 
loss.  442 
 443 
Although depression is an understandable reaction to AMD, its high prevalence, 444 
persistence, associated disability, costs, and suicide risk make it a formidable 445 
problem.38--40   The 24% incidence rate of depression that we observed in controls 446 
substantiates this.  Unfortunately, there are no established mechanisms to treat 447 
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depression in ophthalmologic settings.  If depression were recognized, referral to 448 
primary care physicians alone would not meet patients’ vision rehabilitative needs.  We 449 
developed a treatment alternative based on evidenced-based practice that screened for 450 
depression, increased linkages to LVR, and trained occupational therapists to deliver 451 
Behavior Activation.  We standardized the intervention to facilitate its dissemination and 452 
drew on current Medicare reimbursement policies to support it, although Medicare does 453 
not reimburse for vision assistive equipment.41  In its current form, BA+LVR can serve 454 
as an initial treatment model to prevent depression in vision-impaired populations.   Few 455 
occupational therapists, however, receive formal training in psychotherapies like BA to 456 
counter depression, and many ophthalmologists fail to refer patients to LVR.  Thus, 457 
treatments like BA+LVR are not currently available.  To become part of routine 458 
ophthalmologic care would require a commitment to comprehensive interdisciplinary 459 
care and financial investment to support standardized depression screening, psychiatric 460 
consultation, care coordination, and clinical and administrative staff training.   461 
 462 
The cost savings of preventing depression are substantial because patients with 463 
depression have significantly higher total healthcare costs than nondepressed patients 464 
($20,046 vs. $11,956).42  In this context, BA+LVR aligns with the intent of the Affordable 465 
Care Act, capitation-based contracts, and pay-for performance reimbursement 466 
strategies which support cost-lowering and quality-improving interprofessional 467 
interventions.  As the population ages and the number of persons with AMD increases, 468 
the personal losses, disability, and costs of AMD will rise. This clinical trial suggests that 469 
increasing interactions between ophthalmology, optometry, rehabilitation, psychiatry, 470 
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and behavioral psychology can improve how we deliver care and achieve better 471 
outcomes for patients with AMD.   472 
 473 
 474 
 475 
 476 
 477 
 478 
 479 
 480 
 481 
 482 
 483 
 484 
 485 
 486 
 487 
 488 
 489 
 490 
 491 
 492 
 493 
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